Hyaluronidase/ocrelizumab Disease Interactions

The use of ocrelizumab is contraindicated in patients with an active hepatitis B virus (HBV) infection. Patients should be screened for HBV prior to treatment initiation. It is recommended to consult a liver disease expert before starting and during treatment with ocrelizumab in patients who are negative for surface antigen [HBsAg] and positive for HB core antibody [HBcAb+] or are carriers of HBV [HBsAg+].

Ocrelizumab may increase the risk of malignancies, including breast cancer. It is recommended to follow standard breast cancer screening guidelines. Exercise care when using this agent in patients with a history of breast cancer or other type of malignancy. Monitor closely for the development of any sign or symptom suggestive of a malignancy and treat appropriately.

Ocrelizumab may increase the risk for upper respiratory tract infections, lower respiratory tract infections, skin infections, and herpes-related infections. It is recommended to delay the use of ocrelizumab in patients with an active infection until the infection is resolved.

The use of live-attenuated or live vaccines is not recommended during treatment with ocrelizumab and until B-cell repletion is confirmed. It is recommended to administer all immunizations according to immunization guidelines at least 4 weeks prior to initiation of ocrelizumab for live or live-attenuated vaccines and, whenever possible, at least 2 weeks prior to initiation of treatment for non-live vaccines. Ocrelizumab may interfere with the effectiveness of non-live vaccines.